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The biological activities of human (hGH) and bovine (bGH) growth hormone derivatives obtained by chem- 
ical modification of the lysine residues were studied by radioreceptor assays using rabbit liver homogenates 
for somatotropic activity (SA). Control treatment with BH; had a very slight effect on the SA, whereas 
the methylation and ethylation drastically reduced the acitivty of both hormones. Guanidination of these 
hormones and even acetimidination at a lower rate are accompanied by a considerable loss of biological 
activity. These results show the involvement of lysine residues in the interaction of hGH and bGH with 
somatotropic receptors. The structure-function relationship of these molecules is discussed, suggesting that 
the lysine or arginine residues in positions 41,64, 70 and 115 might be particularly implicated. 
Human growth hormone Bovine growth hormone Human chorionic somatomammotropin 
Lysine residue 
1. INTRODUCTION 
Though highly purified preparations of bGH 
and hGH have been available for several years, our 
knowledge on the relationship between the 
chemical structure and biological activity of 
growth hormones is limited. We know that the 
biological activity is preserved after reduction of 
the disulfide bonds if the -SH groups are blocked 
by iodoacetamide. Modification of the tryptophan 
or some tyrosine residues, oxidation of the 
methionines can be achieved without or with only 
a partial loss of the growth-promoting activity 
[l-4]. Using enzymic cleavage and association of 
the NHz-terminal hGH fragment l-134 with syn- 
thetic COOH-terminal fragments it was shown 
that full promoting activity can be obtained when 
fragment 1-134 is recombined with a 140-191 
peptide with very similar sequence to that of the 
natural hGH. The NHz-terminal segment I-134 
alone exhibited only 14% of the biological activity 
[1,5-71. 
The fact that a bacterially synthesized methionyl 
Receptor 
hGH is fully active suggests that the a-NH2 group 
of the N-terminal Phe can be modified without loss 
of biological activity [8]. Nothing is known about 
the intervention of the e-NH2 in the growth- 
promoting activity of these hormones. We have 
studied the effect of a more or less profound 
modification of these groups on the biological ac- 
tivity. Only chemical modifications preserving the 
basicity of the group (methylation, ethylation, 
guanidination and acetimidination) were achieved, 
since the abolition of positive charges can cause 
secondary effects on the conformation of the pro- 
tein. The biological activity was investigated using 
a radioligand receptor assay with rabbit liver 
homogenates. 
2. MATERIALS AND METHODS 
2.1. Chemical modifications 
bGH was a highly purified preparation pur- 
chased from Pentex (Miles) (1 IU/mg) and hGH 
was a gift from Dr Dray (Institut Pasteur, Paris) 
(1 IU/mg). 
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2.1.1. Reductive alkylation 
Reductive methylation and ethylation were car- 
ried out by addition of sodium borohydride and 
formaldehyde or acetaldehyde to the hormone 
(0.5-1.0 mg) dissolved in borate buffer (pH 9) as 
in [9]. The solutions were dialyzed against pyridine 
solution (1 olo) and freeze-dried. Determinations of 
lysine, methyl- and ethyllysine were made using a 
Technicon autoanalyzer and elution gradients con- 
taining isopropanol [9,10]. A blank for biological 
assays was prepared by treating hormone with 
borohydride and borate buffer (pH 9, no added 
aldehyde). 
2.1.2. Guanidination 
This reaction was performed using 0.3 M O- 
methylisourea sulfate (Aldrich, Europe) at pH 10.3 
and 5°C (0.7 mg GH/0.15 ml) for 24 h. At the end 
of the reaction, the solutions were dialyzed against 
pyridine solutions. After 1 day of reaction, the 
solutions became slightly opalescent. In both 
cases, the solutions were centrifuged and the 
precipitate discarded. The degree of guanidination 
was measured by amino acid analysis. A blank was 
prepared by treatment of the hormone at pH 10.4 
for 5 days at 5°C. 
2.1.3. Acetimidination 
To obtain a low degree of chemical modifica- 
tion, this reaction was performed at a low concen- 
tration of reagent (ethylacetimidate hydrochloride, 
Aldrich) for 24 h, at pH 10 and 5°C. Determina- 
tion of the e-acetimidyllysine was performed by 
amino acid analysis as in [I 11. 
2.2. Radioreceptor 
activity 
This activity was 
assay of growth-promoting 
determined by radioreceptor 
assay [12] with membranes of rabbit liver on day 
17 of pregnancy in the presence of ‘2SI-labelled 
Pentex bovine growth hormone (bGH) and stan- 
dard unlabelled bGH (Pentex, 1 IU/mg). In rab- 
bit, the liver is particularly rich in GH receptors 
and poor in prolactin receptors. Each sample was 
tested several times in duplicate at various dilu- 
tions in the following buffer: 25 mM Tris (pH 7.6), 
10 mM MgC12, bovine serum albumin 0.1% (w/v). 
3. RESULTS AND DISCUSSION 
The degree of modification as determined by 
amino acid analysis is shown in table 1 as percen- 
tage and number of modified residues out of the 
total number. As usual the degree of ethylation is 
somewhat lower than that of methylation. The 
more disturbing action of the ethyl group can be 
compensated by a lower degree of modification. 
The degree of guanidination as well as that of 
alkylation was very similar in both hormones. 
The results obtained in the radioreceptor assay 
for somatotropic activity are reported in figs 1 and 
2. Table 2 lists the relative potencies expressed in 
terms of native hormone (percentage). These 
values were calculated by comparison of the hor- 
mone concentration needed for 50% inhibition of 
specific binding. 
As shown in table 2, the reductive action of 
borohydride alone has a very slight effect on the 
biological activity (perhaps as the result of partial 
reduction and disordered reconstitution of 
disulfide bonds as we have observed in the case of 
ovine prolactin; unpublished). The effect of 
methylation or ethylation in reductive conditions is 
much more clear-cut: 50-80% of the activity is 
lost. Guanidination or limited acetimidination lead 
to similar results for hGH but with much more 
Taule 1 
Degree of modification of the lysine residues 
Modified Total 
hormones no.of 
lysine 
residues 
Methylation 
% Number 
Ethylation 
070 Number 
Guanidination 
% Number 
Acetimidination 
% Number 
bGH 11 69 7 45 4-5 66 7 10-20 l-2 
hGH 9 74 7 52 5 52 5 10-20 l-2 
Values denote % and number of modified lysines/molecule 
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Fig.1. Specific binding of native and modified bGH in a radioreceptor assay for somatotropic activity with pregnant 
rabbit liver membranes. The GH activity is expressed in bovine growth hormone equivalents (bGH Pentex, 1 IU/mg) 
(ti); Red-bGH, reduced bGH (A-4); Met-bGH, methylated bGH (y); Am-bGH, acetimidinated bGH 
(H); Et-bGH, ethylated bGH (o---O); Gu-bGH, guanidinated bGH (M). 
drastic loss of activity in the case of bGH. In 
another bioassay (the hypophysectomized rat body 
weight test) Blumgrund de Satz and Santome [ 131 
did not observe a considerable loss of biological 
activity in the case of the amidinated bGH. In our 
test, however, all the lysine-modified derivatives 
exhibit a significant loss of activity when compared 
with the blanks. Examination of the amino acid se- 
quences of different molecules with growth- 
promoting activity shows (see fig.3) the conserva- 
tion of lysine (or arginine) residues at positions (of 
the hGH sequence) 41, 64, 70, 115, 145, 158 and 
168 [14] suggesting that they might play a role in 
the biological activity. In contrast, Lys 29 of bGH 
Table 2 
Biological activity of modified growth hormones (in percentage of native hormone)” 
Hormone BHY, PH 9 Methyl- Ethyl- pH 10 Guanidin- Acetimidin- 
(blank) ated ated (blank) ated ated 
bGH 71 39 27 100 17 11 
hGH 88 13 39 100 58 51 
a Relative potencies expressed as a percentage of the binding activity of native oCS calculated 
by comparison of the hormone concentration needed for 50% inhibition of specific binding 
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Fig.2. Specific binding of native bGH and modified hCH in a radioreceptor assay for somatotropic activity with 
pregnant rabbit liver membranes. The GH activity is expressed in bovine growth hormone quivalents (bGH Pentex, 
1 IU/mg) (&---A); Red-hGH, reduced hGH (ti); Met-hGH, methylated hGH (Q-XI); Am-hGH, acetimidinated 
hGH (H); Et-hGH, ethylated hGH (C----O); Gu-hGH, guanidinated hGH (M). 
is replaced by a glutamine in hGH and Lys 38 of 
hGH by glutamic acid in bGH, a clear indication 
of the non-essential character of these basic 
residues. Recently, peptide segments l-43 and 
32-46 of hGH have been synthesized. These pep- 
tides which contained Lys 41 show some biological 
potency [15] when assayed in an in vitro test based 
on the differentiation of preadipose cells into 
adipose cells [16,17]. As mentioned in section 1, 
the contribution to the activity of segment 135-146 
[I ,151 {and therefore of Lys 140 and Lys 145) 
seems negligible and those of segment 146-191 
(containing lysine residues 158 and 168) most likely 
secondary. It is interesting to point out that in 
position 64 hGH possesses an arginine residue 
{which is not modified by our reagents) whereas 
bGH possesses a lysine residue. This difference 
298 
might explain the more considerable loss of 
biological activity observed in the case of 
guanidinated (or acetimidinated) bGH and sug- 
gests that a positive charge at this point of the se- 
quence might play a role in the interaction with the 
receptors. A closely related molecuies hCS, de- 
prived of growth-promoting activity but with 
almost the same sequence as hGH, possesses at this 
point a methionine residue instead of a basic 
residue (Lys or Arg) [ 191. 
It may be concluded from these results that 
several lysine derived positive charges (including 
the 64 residue) significantly contribute to the bind- 
ing of the growth hormone to its rabbit liver recep- 
tor. We reported recently that the same kind of 
chemical modification is accompanied in the case 
of oCS, another hormone with somatotropic ac- 
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Fig.3. Comparison of primary sequences of human and 
bovine growth hormones. Amino acid (-o-); GAP 
( ); lysine (L); different amino acid in the bGH 
sequence (not in the line) (0); position occupied by a 
lysine residue in all growth hormones (0); residue is 
occupied by lysine in growth hormones, prolactins and 
human chorionic somatomammotropin (hCS) (0). 
tivity but with unknown amino acid sequence, by 
a similar or even more drastic loss of biological ac- 
tivity [20]. Thus, residues 41, 64, 70 and 115 are 
more suitable to play a role not only because a 
basic residue is always preserved at this position in 
the GH molecules but also because some of these 
residues seem to be located in an exposed segment 
as shown by the reactivity of Tyr 42 [3,13] or by 
immunological studies with monoclonal antibodies 
WI. 
Residue 115 could also play an important role in 
relation with the prolactin activity since it is com- 
mon to all the molecules of the prolactin family. 
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